Literature DB >> 26537862

THERAPY OF ENDOCRINE DISEASE: Testosterone supplementation and body composition: results from a meta-analysis study.

Giovanni Corona, Vito A Giagulli1, Elisa Maseroli1, Linda Vignozzi1, Antonio Aversa1, Michael Zitzmann1, Farid Saad2, Edoardo Mannucci1, Mario Maggi3.   

Abstract

OBJECTIVE: The role of testosterone (T) in regulating body composition is conflicting. Thus, our goal is to meta-analyse the effects of T supplementation (TS) on body composition and metabolic outcomes.
METHODS: All randomized controlled trials (RCTs) comparing the effect of TS on different endpoints were considered.
RESULTS: Overall, 59 trials were included in the study enrolling 3029 and 2049 patients in TS and control groups respectively. TS was associated with any significant modification in body weight, waist circumference and BMI. Conversely, TS was associated with a significant reduction in fat and with an increase in lean mass as well as with a reduction of fasting glycaemia and insulin resistance. The effect on fasting glycaemia was even higher in younger individuals and in those with metabolic diseases. When only RCTs enrolling hypogonadal (total T <12  mol/l) subjects were considered, a reduction of total cholesterol as well as triglyceride (TGs) levels were also detected. Conversely, an improvement in HDL cholesterol levels as well as in both systolic and diastolic blood pressure was not observed.
CONCLUSION: Our data suggest that TS is able to improve body composition and glycometabolic profile particularly in younger subjects and in those with metabolic disturbances. Specifically designed studies are urgently needed to confirm this point.
© 2016 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26537862     DOI: 10.1530/EJE-15-0262

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  50 in total

Review 1.  Testosterone supplementation and body composition: results from a meta-analysis of observational studies.

Authors:  G Corona; V A Giagulli; E Maseroli; L Vignozzi; A Aversa; M Zitzmann; F Saad; E Mannucci; M Maggi
Journal:  J Endocrinol Invest       Date:  2016-05-30       Impact factor: 4.256

2.  Reduction of calprotectin and phosphate during testosterone therapy in aging men: a randomized controlled trial.

Authors:  L Pedersen; L L Christensen; S M Pedersen; M Andersen
Journal:  J Endocrinol Invest       Date:  2016-12-20       Impact factor: 4.256

3.  Testosterone vs. aromatase inhibitor in older men with low testosterone: effects on cardiometabolic parameters.

Authors:  J P Dias; M D Shardell; O D Carlson; D Melvin; G Caturegli; L Ferrucci; C W Chia; J M Egan; S Basaria
Journal:  Andrology       Date:  2016-10-28       Impact factor: 3.842

Review 4.  Paediatric and adult-onset male hypogonadism.

Authors:  Andrea Salonia; Giulia Rastrelli; Geoffrey Hackett; Stephanie B Seminara; Ilpo T Huhtaniemi; Rodolfo A Rey; Wayne J G Hellstrom; Mark R Palmert; Giovanni Corona; Gert R Dohle; Mohit Khera; Yee-Ming Chan; Mario Maggi
Journal:  Nat Rev Dis Primers       Date:  2019-05-30       Impact factor: 52.329

Review 5.  Klinefelter syndrome: cardiovascular abnormalities and metabolic disorders.

Authors:  A E Calogero; V A Giagulli; L M Mongioì; V Triggiani; A F Radicioni; E A Jannini; D Pasquali
Journal:  J Endocrinol Invest       Date:  2017-03-03       Impact factor: 4.256

6.  Changes in white adipose tissue gene expression in a randomized control trial of dieting obese men with lowered serum testosterone alone or in combination with testosterone treatment.

Authors:  Mathis Grossmann; Mark Ng Tang Fui; Tian Nie; Rudolf Hoermann; Michele V Clarke; Ada S Cheung; Jeffrey D Zajac; Rachel A Davey
Journal:  Endocrine       Date:  2021-04-17       Impact factor: 3.633

7.  Influence of vitamin D levels on the cardiovascular profile of hypogonadal men.

Authors:  G Tirabassi; M Cutini; G Salvio; G Cerqueni; A Lenzi; G Balercia
Journal:  J Endocrinol Invest       Date:  2017-04-08       Impact factor: 4.256

Review 8.  Enclomiphene citrate for the treatment of secondary male hypogonadism.

Authors:  Katherine M Rodriguez; Alexander W Pastuszak; Larry I Lipshultz
Journal:  Expert Opin Pharmacother       Date:  2016-07-04       Impact factor: 3.889

9.  Predictors and clinical consequences of starting androgen therapy in men with low testosterone: results from the SIAMO-NOI registry.

Authors:  G Rastrelli; L Giovannini; A E Calogero; D Gianfrilli; E Serra; A Pizzocaro; V A Giagulli; G Motta; G Vancieri; A Sperandio; S Andò; R Selice; G Luca; F Cocchiara; D Canale; M Maggi
Journal:  J Endocrinol Invest       Date:  2016-04-01       Impact factor: 4.256

10.  Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial.

Authors:  Glenn R Cunningham; Susan S Ellenberg; Shalender Bhasin; Alvin M Matsumoto; J Kellogg Parsons; Peter Preston; Jane A Cauley; Thomas M Gill; Ronald S Swerdloff; Christina Wang; Kristine E Ensrud; Cora E Lewis; Marco Pahor; Jill P Crandall; Mark E Molitch; Denise Cifelli; Shehzad Basaria; Susan J Diem; Alisa J Stephens-Shields; Xiaoling Hou; Peter J Snyder
Journal:  J Clin Endocrinol Metab       Date:  2019-12-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.